SARS-CoV-2 and the rheumatology patient: the last 12 months and a boost in the future

Winthrop, Kevin; Whitley, Richard J.; Aletaha, Daniel

doi:10.1136/annrheumdis-2021-221251

Cited by 7 publications

(5 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MCV-COV1901 has emergency authorization use in Taiwan as of July 2021, 19 and has since advanced to larger clinical trials, including a trial initiated by WHO. 50 Additional information accumulates from these trials, but further studies are needed to see if PWH require distinct immunization strategies with improved immunogenicity, such as boosters or additional doses, 51,52 heterologous revaccination, 53 or higher doses as with hepatitis B 54 and that for in uenza vaccine 55 . Chen, Ching-Tai Huang, Hsiao-Ting Chang, Shinn-Jang Hwang, Ning-Chi Wang, Ming-Che Liu , Yu-Lin Lee, , Tzou-Yien Lin, and Wen-Sen Lee had nothing to declare.…”

Section: Discussionmentioning

confidence: 99%

A retrospective study of the safety and immunogenicity of MVC-COV1901 vaccine for people living with HIV

Cheng

Lien²,

Hsieh

et al. 2022

Preprint

View full text Add to dashboard Cite

Safety and immunogenicity of MVC-COV1901, a recombinant COVID-19 protein vaccine, containing S-2P protein adjuvanted with CpG 1018 and aluminium hydroxide, was assessed for people living with HIV (PWH). A total of 57 PWH of ≥ 20 years of age who are on stable antiretroviral therapy were compared with 882 HIV-negative participants. Participants received 2 doses of MVC-COV1901 28 days apart. No vaccine-related serious adverse events (SAEs) were recorded. Seroconversion rates (SCRs) of 100% and 99.8% were achieved in PWH and comparators, respectively, 28 days after second dose. After adjusting for sex, age, BMI category, and comorbidity, the adjusted GMT ratio of comparator/PWH was 3.2 (95% CI 2.5-4). A higher CD4/CD8 ratio was associated with a higher GMT (R = 0.27, p = 0.039). MVC-COV1901 has shown robust safety but elicited weaker immune responses in PWH. As a result, a third dose or booster doses of MVC-COV1901 may be appropriate for PWH.ClinicalTrials.gov registration: NCT04695652.

show abstract

Section: Discussionmentioning

confidence: 99%

A retrospective study of the safety and immunogenicity of MVC-COV1901 vaccine for people living with HIV

Cheng

Lien²,

Hsieh

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

“…MCV-COV1901 has emergency authorization use in Taiwan as of 19 July 2021 and has since advanced to larger clinical trials, including a trial initiated by the WHO [ 52 ]. Additional information accumulates from these trials, but further studies are needed to see if PWH require distinct immunization strategies with improved immunogenicity, such as boosters or additional doses [ 53 , 54 ], heterologous revaccination [ 55 ], or higher doses as with hepatitis B [ 56 ] and that for the influenza vaccine [ 57 ]. These studies may include, at this point, effectiveness studies focusing on PWH, which may justify the use of strategies such as additional doses of the vaccine or heterologous boosting.…”

Section: Discussionmentioning

confidence: 99%

A Retrospective Study of the Safety and Immunogenicity of MVC-COV1901 Vaccine for People Living with HIV

et al. 2022

View full text Add to dashboard Cite

Background: This study aimed to assess the safety and immunogenicity of MVC-COV1901, a recombinant COVID-19 protein vaccine, containing S-2P protein adjuvanted with CpG 1018 and aluminum hydroxide, for people living with HIV (PWH). Methods: A total of 57 PWH of ≥20 years of age who are on stable antiretroviral therapy were compared with 882 HIV-negative participants. Participants received two doses of MVC-COV1901 28 days apart. Results: No vaccine-related serious adverse events (SAEs) were recorded. Seroconversion rates (SCRs) of 100% and 99.8% were achieved in PWH and comparators, respectively, 28 days after the second dose. After adjusting for sex, age, BMI category, and comorbidity, the adjusted GMT ratio of comparator/PWH was 3.2 (95% CI 2.5–4). A higher CD4/CD8 ratio was associated with a higher GMT (R = 0.27, p = 0.039). MVC-COV1901 has shown robust safety but elicited weaker immune responses in PWH. Conclusions: Further investigations may be needed to determine whether PWH require distinct immunization strategies with improved immunogenicity. The main study is registered at ClinicalTrials.gov (NCT04695652).

show abstract

“…The pandemic has clearly taught us how fast modern science can develop vaccines and what having vaccines may mean for rheumatology. 1 It has taught us to better manage and guide our patients in an unusual situation, from distant consultations to protection from infection 2 and provided new lessons on the importance of T-cell immunity on vaccination. [3][4][5] Nevertheless, the conundrum continues: why do so many people contract SARS-CoV2 infection despite having been vaccinated and/or previously experienced the infection?…”

Section: Josef S Smolenmentioning

confidence: 99%

“…The pandemic has clearly taught us how fast modern science can develop vaccines and what having vaccines may mean for rheumatology 1. It has taught us to better manage and guide our patients in an unusual situation, from distant consultations to protection from infection2 and provided new lessons on the importance of T-cell immunity on vaccination 3–5.…”

mentioning

confidence: 99%

Greetings from the editor 2023/2

Smolen

2023

Ann Rheum Dis

View full text Add to dashboard Cite

SARS-CoV-2 and the rheumatology patient: the last 12 months and a boost in the future

Cited by 7 publications

References 56 publications

A retrospective study of the safety and immunogenicity of MVC-COV1901 vaccine for people living with HIV

A retrospective study of the safety and immunogenicity of MVC-COV1901 vaccine for people living with HIV

A Retrospective Study of the Safety and Immunogenicity of MVC-COV1901 Vaccine for People Living with HIV

Greetings from the editor 2023/2

Contact Info

Product

Resources

About